Following a FDA advisory committee meeting on June 10, 2024, where they committee voted to recommend approval of Eli Lilly's new Alzheimer's disease treatment drug Kisunla (donanemab), FDA issued an approval for its general use on July 2, 2024. Expectations are that this drug will help adults with intellectual disability living with dementia, and eventually apply also to adults with Down syndrome (after safety issues are addressed).